Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
Authors
Keywords
Overall Survival, Minor Component, Lung Adenocarcinoma, Metastatic Rate, Electronic Supplementary Table
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 23, Issue 6, Pages 2099-2105
Publisher
Springer Nature
Online
2016-02-03
DOI
10.1245/s10434-015-5043-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Impact of Minimal Micropapillary Pattern in Invasive Lung Adenocarcinoma
- (2015) Geewon Lee et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Solid Component and Tumor Size Correlate With Prognosis of Stage IB Lung Adenocarcinoma
- (2015) Songtao Xu et al. ANNALS OF THORACIC SURGERY
- Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma
- (2015) Norifumi Tsubokawa et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma
- (2015) Yi-Chen Yeh et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival
- (2015) Hideki Ujiie et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease
- (2014) A. D. Campos-Parra et al. EUROPEAN RESPIRATORY JOURNAL
- Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival
- (2014) Jung-Jyh Hung et al. JOURNAL OF CLINICAL ONCOLOGY
- A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component
- (2014) Yang Zhang et al. Journal of Thoracic Oncology
- The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma
- (2014) Yang Zhang et al. Scientific Reports
- Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller
- (2013) Jun-ichi Nitadori et al. JNCI-Journal of the National Cancer Institute
- Micropapillary and solid subtypes of invasive lung adenocarcinoma: Clinical predictors of histopathology and outcome
- (2013) Min Jae Cha et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients
- (2013) Prudence A. Russell et al. Journal of Thoracic Oncology
- The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
- (2012) Arne Warth et al. JOURNAL OF CLINICAL ONCOLOGY
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
- (2011) Akihiko Yoshizawa et al. MODERN PATHOLOGY
- Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study
- (2009) Giorgio V. Scagliotti et al. EUROPEAN JOURNAL OF CANCER
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- (2009) Tudor Ciuleanu et al. LANCET
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
- (2009) G. Scagliotti et al. ONCOLOGIST
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started